Overview

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gemcitabine